Linked Life Data

16025262

Source:http://linkedlifedata.com/resource/pubmed/id/16025262

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16025262rdf:typepubmed:Citationlld:pubmed
pubmed-article:16025262lifeskim:mentionsumls-concept:C1140680lld:lifeskim
pubmed-article:16025262lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:16025262lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:16025262lifeskim:mentionsumls-concept:C0079083lld:lifeskim
pubmed-article:16025262lifeskim:mentionsumls-concept:C0015020lld:lifeskim
pubmed-article:16025262lifeskim:mentionsumls-concept:C0598958lld:lifeskim
pubmed-article:16025262lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:16025262lifeskim:mentionsumls-concept:C1708063lld:lifeskim
pubmed-article:16025262lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:16025262lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:16025262pubmed:issue10lld:pubmed
pubmed-article:16025262pubmed:dateCreated2005-9-27lld:pubmed
pubmed-article:16025262pubmed:abstractTextNeurotoxicity is a common side effect of platinum/taxane-based therapy of ovarian cancer. We performed a double-blind randomized placebo-controlled trial to evaluate the influence of the cytoprotectant amifostine on the neurotoxicity of first-line therapy of ovarian cancer with paclitaxel/carboplatin with or without epirubicin.lld:pubmed
pubmed-article:16025262pubmed:languageenglld:pubmed
pubmed-article:16025262pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025262pubmed:citationSubsetIMlld:pubmed
pubmed-article:16025262pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025262pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025262pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025262pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025262pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025262pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025262pubmed:statusMEDLINElld:pubmed
pubmed-article:16025262pubmed:monthOctlld:pubmed
pubmed-article:16025262pubmed:issn0941-4355lld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:HilpertFFlld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:RichterBBlld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:BurgesAAlld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:HeilmannVVlld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:du BoisAAlld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:RallK LKLlld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:RossnerDDlld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:SpätheKKlld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:StähleAAlld:pubmed
pubmed-article:16025262pubmed:authorpubmed-author:Arbeitsgemein...lld:pubmed
pubmed-article:16025262pubmed:issnTypePrintlld:pubmed
pubmed-article:16025262pubmed:volume13lld:pubmed
pubmed-article:16025262pubmed:ownerNLMlld:pubmed
pubmed-article:16025262pubmed:authorsCompleteYlld:pubmed
pubmed-article:16025262pubmed:pagination797-805lld:pubmed
pubmed-article:16025262pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:meshHeadingpubmed-meshheading:16025262...lld:pubmed
pubmed-article:16025262pubmed:year2005lld:pubmed
pubmed-article:16025262pubmed:articleTitleNeuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.lld:pubmed
pubmed-article:16025262pubmed:affiliationKlinik für Gynäkologie und Geburtshilfe, Campus Kiel Universitätsklinikum Schleswig-Holstein, Michaelisstrasse 16, 24105 Kiel, Germany. fhilpert@email.uni-kiel.delld:pubmed
pubmed-article:16025262pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16025262pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:16025262pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16025262pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16025262lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16025262lld:pubmed